

FOR IMMEDIATE RELEASE:

**DR. JEFFREY GELFAND, M.D. JOINS SCIENTIFIC ADVISORY BOARD OF
EBI**

McLean, VA, May 12, 2009 – Dr. Jeffrey Gelfand has accepted a position on the Scientific Advisory Board of Exponential Biotherapies, Inc. (“EBI”). Dr. Gelfand, who is recognized for his laboratory and clinical research in immunology, inflammation, infection, and tumor biology, is currently a Clinical Professor of Medicine at Harvard Medical School. Since 2000, he has also served as program leader at the Center for Integration of Medicine and Innovative Technology (“CIMIT”), a non-profit consortium of Boston teaching hospitals and engineering schools, including Harvard, MIT and Boston University. He has served as the Chairman of the Department of Medicine of Tufts University School of Medicine and Physician-in-Chief at the New England Medical Center. As a graduate of the Tufts University School of Medicine, Dr. Gelfand completed his clinical training at the Johns Hopkins Hospital and the National Institutes of Health. Dr. Gelfand brings to EBI not only his research expertise as documented in 90 scientific publications and 45 chapters in leading textbooks of medicine, but also his clinical experience as a board-certified physician in internal medicine, infectious diseases, and clinical immunology and allergy.

EBI is a privately held, McLean, Virginia based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat a wide range of severe inflammatory disorders such as acute kidney injury, septic shock, radiation sickness and avian influenza infections. The Company’s compounds represent a new class of immune regulating therapeutic agents. EBI’s first candidate drug, EA-230, is currently about to enter into Phase 2 clinical trials.

Forward-looking statements

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks as to the adequacy of the proceeds of the financing to satisfy our financial requirements; risks related to the progress, timing and results of clinical trials; risks that subsequent clinical trials may show our candidate compounds are not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of any of our product candidates; manufacturing issues relating to any of our drug candidates; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

Contact:

Zsolt Harsanyi, Ph.D., Chairman and CEO: 703-883-3701